Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Solid Tumor Malignancies

Interventions

DRUG

Imetelstat Sodium (GRN163L)

Dose increase by 25% if tolerated infused over 2 hours

Trial Locations (2)

Wayne State University, Karmanos Cancer Center, Detroit

The University of Chicago Medical Center, Chicago